A Case of ALK-rearranged Lung Cancer with a Durable Response to Atezolizumab Plus Bevacizumab/Carboplatin/Paclitaxel Combination Therapy After Initial Resistance to Alectinib
Abstract:━━ Background. In anaplastic lymphoma kinase (ALK)-rearranged lung cancer, ALK tyrosine kinase inhibitors have been reported to significantly prolong the progression free survival versus platinum-based combination therapy. In contrast, the effect of immune checkpoint inhibitors has been reported to be limited. We herein report a case of initial resistance to alectinib with a durable response to atezolizumab plus bevacizumab/carboplatin/paclitaxel combination therapy. Case. A 74-year-old woman with cough was re… Show more
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.